Results 271 to 280 of about 257,826 (338)

Successful Treatment of a 42-Year-Old Man with Concurrent Anti-Glomerular Basement Membrane Disease and Anti-Phospholipase A2 Receptor Antibody-Positive Membranous Nephropathy: A Case Report. [PDF]

Am J Case Rep
Hu C, Wang J, Zhan Y, Lu J, Ye J, Chen J, Zhou W, Qi C, Zhang M, Gu L, Jiang N.   +10 more
europepmc   +1 more source

Hematopoietic stem cell transplantation in Crohn's disease: a comprehensive review. [PDF]

Curr Opin Gastroenterol
Gupta A, Ricart E, Cohen L.
europepmc   +1 more source

Robust CAR T‐cell expansion and superior outcomes in DLBCL patients in complete response at infusion

British Journal of Haematology, EarlyView.
In this study, CAR T‐cell expansion and persistence were found to be comparable between CR and non‐CR groups, regardless of the co‐stimulatory domain (CD28 or 4‐1BB) or product used. Furthermore, peripheral blood kinetics—including absolute counts and proportions of total, CD4+ and CD8+ CAR T cells—showed no significant differences between the two ...
Ryo Hanajiri, Hiroya Wakabayashi, Kohei Ishigiwa, Fumiya Ohara, Shiho Hirano, Hirofumi Yokota, Shihomi Kuwano, Katsuya Furukawa, Kazuyuki Shimada, Takahiko Sato, Seitaro Terakura, Hitoshi Kiyoi   +11 more
wiley   +1 more source

Transcriptome analysis to decipher the molecular underpinnings of response to treatment in systemic lupus erythematosus. [PDF]

RMD Open
Garantziotis P, Moysidou GS, Kapsala N, Flouda S, Nikolopoulos D, Chavatza K, Sentis G, Filia A, Malissovas N, Pieta A, Banos A, Katechis S, Fanouriakis A, Bertsias G, Boumpas DT.   +14 more
europepmc   +1 more source

Copanlisib in combination with rituximab and bendamustine for transplant‐ineligible relapsed/refractory diffuse large B‐cell lymphoma patients: Results from the phase II multicentre FIL Copa‐BR trial from Fondazione Italiana Linfomi (FIL)

British Journal of Haematology, EarlyView.
A phase II, single‐arm, multicentre trial was conducted by Fondazione Italiana Linfomi (FIL) to investigate the combination of copanlisib plus rituximab and bendamustine (copa‐BR) in transplant‐ and chimeric antigen receptor (CAR)‐T‐ineligible relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL). Thirty‐seven patients were enrolled.
Mattia Novo, Pio Manlio Mirko Frascione, Alessia Castellino, Luigi Marcheselli, Samantha Deianira Dattoli, Margherita Vannucchi, Delia Rota‐Scalabrini, Alessandra Tucci, Guido Gini, Giuseppe Tarantini, Donato Mannina, Annalisa Arcari, Arcangelo Liso, Elisabetta Scarpa, Dario Marino, Michele Spina, Ausilia Gorgone, Nicola Di Renzo, Salvatrice Mancuso, Luigi Petrucci, Agostino Tafuri, Barbara Botto, Francesca Bonello, Elisa Santambrogio, Umberto Vitolo   +24 more
wiley   +1 more source

Real-World Outcomes of PET-Adapted Treatment for Classic Hodgkin's Lymphoma: A Study From a Single Tertiary Care Center. [PDF]

Cureus
Iftikhar I, Abbas M, Afzal M, Bilal H, Uzair M, Qasim M, Ahsan B, Ahmad U, Imam Bokhari SW.   +8 more
europepmc   +1 more source

Efficacy and safety of rituximab for membranous nephropathy in adults: a meta-analysis of RCT. [PDF]

Front Nephrol
Mao B, Han J, Wang J, Ye K.
europepmc   +1 more source

Current status of transplantation surgery [PDF]

, 1973
Starzl, TE
core  

Artemisinins in autoimmune diseases: effects and mechanisms in systemic lupus erythematosus and rheumatoid arthritis

British Journal of Pharmacology, EarlyView.
Abstract Autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) result from immune self‐tolerance loss, causing tissue damage. Standard treatments targeting late‐stage inflammation often have serious side effects. Artemisinin, known for its antimalarial properties, shows potential immunomodulatory effects.
Fanchao Zhou, Guoming Li, Ruixiang Tan, Guodong Wu, Changsheng Deng   +4 more
wiley   +1 more source